文献速递膀胱癌与上尿路尿路上皮癌

临床完全缓解能否替代病理完全缓解指导膀胱癌保膀胱策略:系统综述与荟萃分析

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.
PubMed 文献 · BJU Int · 2026-03-16

cCR与pCR的一致性仅0.51(95%CI 0.42-0.60),非cCR与非pCR一致性为0.84(95%CI 0.70-0.92)。现有证据不支持仅凭cCR定义指导治疗决策。

要点

  • cCR与pCR一致性仅0.51,cCR对pCR预测能力差。
  • 非cCR与非pCR一致性较高(0.84),阴性预测价值较好。
  • 多数研究存在中等偏倚风险,cCR评估方法异质性大。

核心结论

  • 现有证据不支持仅依赖当前cCR定义指导MIBC治疗决策,因其对pCR预测不佳。

研究设计与样本

  • 前瞻性注册的系统综述与荟萃分析(CRD420251066540),检索MEDLINE、EMBASE和Web of Science(2025年6月),纳入10项回顾性(n=894)和3项前瞻性(n=181)研究,共1075例接受新辅助治疗后的肌层浸润性膀胱癌(MIBC)患者。

主要发现

  • cCR与pCR的一致性为0.51(95%CI 0.42-0.60,n=779,9项研究)。
  • 非cCR与非pCR的一致性为0.84(95%CI 0.70-0.92,n=536,7项研究)。
  • cCR评估方法包括经尿道膀胱肿瘤电切(TURB,n=188,2项研究)、计算机断层扫描(n=221,2项研究)、磁共振成像(MRI,n=122,2项研究)、氟脱氧葡萄糖正电子发射断层扫描(n=45)等。

临床怎么用

  • 当前cCR定义不足以单独指导保膀胱策略,需结合更精准的评估手段。
  • MRI联合TURB及尿液/血液循环肿瘤DNA(ctDNA)可能优化cCR评估。

局限性

  • 多数研究存在中等偏倚风险,一项研究因膀胱镜评估的检查者依赖偏倚评为严重风险。
  • cCR评估方法异质性大,部分研究样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the concordance between clinical complete response (cCR) and pathological complete response (pCR) in muscle-invasive bladder cancer (MIBC) to assess the surrogacy and prognostic value of cCR for guiding bladder-sparing strategies. METHODS: In this prospectively registered systematic review and meta-analysis (CRD420251066540), we searched MEDLINE, EMBASE, and Web of Science in June 2025 for studies reporting clinical and pathological complete response rates in patients with MIBC undergoing neoadjuvant therapy followed by radical cystectomy (RC). Pooled concordance was estimated via random-effects meta-analysis. Risk-of-bias was assessed using the Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I). RESULTS: Out of 1947 individual records, 10 (n = 894) retrospective and three (n = 181) prospective studies comprising 1075 patients were included. Restaging modalities for cCR assessment included transurethral resection of the bladder (TURB; n = 188, two studies), computed tomography (n = 221, two studies), magnetic resonance imaging (MRI; n = 122, two studies), and fluorodeoxyglucose positron emission tomography (n = 45). One study (n = 56) used perioperative cystoscopy, while the remaining five studies (n = 499) combined imaging with cystoscopy or TURB. The concordance (n = 779, nine studies) between cCR and pCR was 0.51 (95% confidence interval [CI] 0.42-0.60), the concordance (n = 536, seven studies) between non-cCR and non-pCR was 0.84 (95% CI 0.70-0.92). Most studies were rated as having moderate concerns regarding bias, and one as serious due to examiner-dependent bias of cystoscopy-based cCR assessment. CONCLUSION: Current evidence does not support relying on the current definition of cCR alone, which poorly predicts pCR, to guide treatment decisions. Ongoing trials assessing the combination of MRI plus TURB with urine and/or blood based circulating tumour DNA may help refine cCR evaluation and support the sole introduction of bladder-sparing approaches in patients with MIBC who respond to neoadjuvant systemic therapy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Roessler N, Miszczyk M, Gontero P, et al. Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis. BJU Int. 2026. PMID: 41839747. doi:10.1111/bju.70214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。